By

Gisela Pairo
Creating a collaborative environment integrated by a diversity of stakeholders is vital to move forward on the innovative paradigm of Integrated Research Platforms (IRPs). Next October, experts from health authorities, ethic committees, patient organizations, health technology assessments, industry/pharmaceutical companies and academic investigators/hospital networks involved in drug development are called to attend EU-PEARL’s first Stakeholder Workshop...
Read More
Around 300 Consortium members are called to attend EU-PEARL second General Assembly Meeting (GAM) organised along four half-day sessions during September and October. All sessions will take place online due to the restrictions imposed by COVID-19. Besides, representing an excellent opportunity to keep the full Consortium abreast of the latest developments in the project, this...
Read More
Key note by Francesco Patalano (Novartis) and Daniel Prieto-Alhambra (University of Oxford). Albeit our different perspectives, we, public and private partners in EU-PEARL share a common responsibility towards society: to improve health outcomes for patients by promoting innovative and more efficient methodologies that enable the timely development of new medicines. Now, the COVID-19 global emergency...
Read More
I work as a marketing and sales director for a large hospitality company and have moved countries often. As the daughter of a French diplomat, I spent many years abroad -I was born in New Caledonia- and later in life, I settled temporarily in Costa Rica, where both my kids where born. There, we enjoyed...
Read More
EU-PEARL is taking further steps to ensure that patients will be at the centre in the new paradigm of clinical trials. So, in the upcoming weeks the Patient Advisory Board (PAG) will take off, whilst a session scheduled for the project’s General Assembly Meeting (GAM) will be devoted to patient engagement. In May, EU PEARL...
Read More
With the aim to bring science and researchers closer to the general public and stimulate interest in research careers – particularly among young people, the European Researchers’ Night will take place next November 27th in a virtual format. Lada Murcia, Biomedical Scientist at Vall d’Hebron Research Institute and project manager at EU-PEARL will deliver and...
Read More
DIA’s Master Protocol Workshop will take place next October 8th and 9th online. The two-day event will focus on design, planning, implementation, and evolving operational best practices through the lens of Master Protocol trial stakeholders. Cecile Spiertz, Senior Director of External Innovation Clinical Trial Platform at Janssen and Benjamin Hofner, Head of Section Biostatistics at...
Read More
Statisticians in the Pharmaceutical Industry (PSI) will hold a webinar on Master protocols – theory, application and regulatory considerations next September 23rd. The event is addressed to experts on master protocols from the pharmaceutical industry, academia, and regulatory agencies. Martin Posch, professor of Medical Statistics at the Medical University of Vienna, head of the Center...
Read More
As patient centric approach has become a top priority in drug development and clinical research, debate intensifies on how best industry and researchers can foster this new model. With a view to continue facilitating dialogue between industry and patient stakeholders, Eye for Pharma 2020 will take place virtually next September 15th and 16th. Valentina Strammiello,...
Read More
The domain of EU-PEARL’s research, Integrated Research Platforms (IRPs) and platform trials is relatively new and consequently the vocabulary is still work in progress.  Hence, the need to develop a common understanding and usage of terminology beyond EU-PEARL. With this goal in mind, D2.1. Report on Terminology, References and Scenarios for Platform Trials and Master...
Read More
1 2